drugset / Trial / NCT03402503

Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

NCT03402503

Phase 2 Completed 52 enrolled IntelGenx Corp.
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this study is to evaluate the safety, feasibility, tolerability and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer's disease.

Timeline

Start
2018-11-26
Primary completion
2024-03-13
Completion
2024-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 10 mg Other
Subject Montelukast Other / unclassified 30 mg Other

Indications